Current status of drugs targeting PDGF/PDGFR

被引：16
作者：
Ai, Jing-Yan [1 ,2 ]
Liu, Chen -Fu [3 ]
Zhang, Wen [1 ,2 ]
Rao, Guo-Wu [1 ,2 ]
机构：
[1] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310014, Peoples R China
[2] Zhejiang Univ Technol, Inst Drug Dev & Chem Biol, Hangzhou 310014, Peoples R China
[3] Gannan Med Univ, Sch Pharmaceut Sci, Ganzhou 341000, Peoples R China
来源：
DRUG DISCOVERY TODAY | 2024年 / 29卷 / 07期
基金：
中国国家自然科学基金;
关键词：
PDGF; PDGFR; monoclonal antibody; PDGFR inhibitors; PROTACs; FACTOR-BETA-RECEPTOR; TYROSINE KINASE INHIBITOR; ACUTE MYELOID-LEUKEMIA; PDGFR-ALPHA; IN-VITRO; GROWTH; CANCER; CELL; ACTIVATION; PROLIFERATION;
D O I：
10.1016/j.drudis.2024.103989
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
As an important proangiogenic factor, platelet -derived growth factor (PDGF) and its receptor PDGFR are highly expressed in a variety of tumors, fibrosis, cardiovascular and neurodegenerative diseases. Targeting the PDGF/PDGFR pathway is therefore a promising therapeutic strategy. At present, a variety of PDGF/PDGFR targeted drugs with potential therapeutic effects have been developed, mainly including PDGF agonists, inhibitors targeting PDGFR and proteolysis targeting chimera (PROTACs). This review clari fies the structure, biological function and disease correlation of PDGF and PDGFR, and it discusses the current status of PDGFR-targeted drugs, so as to provide a reference for subsequent research.
引用
收藏
页数：17
相关论文
共 122 条
[1]   Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors [J].
Adams, Val R. ;
Leggas, Markos .
CLINICAL THERAPEUTICS, 2007, 29 (07) :1338-1353
[2]  
Al-Hadiya Badraddin M H, 2014, Profiles Drug Subst Excip Relat Methodol, V39, P265, DOI 10.1016/B978-0-12-800173-8.00006-4
[3]   PDGF-D gene polymorphism is associated with increased cardiovascular mortality in elderly men [J].
Alehagen, Urban ;
Olsen, Renate S. ;
Lanne, Toste ;
Matussek, Andreas ;
Wagsater, Dick .
BMC MEDICAL GENETICS, 2016, 17
[4]  
Asano Teizo, 2020, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V39, P117, DOI 10.1089/mab.2020.0012
[5]   A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors [J].
Becerra, Carlos R. ;
Conkling, Paul ;
Vogelzang, Nicholas ;
Wu, Hilary ;
Hong, Shengyan ;
Narwal, Rajesh ;
Liang, Meina ;
Tavakkoli, Fatemeh ;
Pandya, Naimish .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) :917-925
[6]   E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models [J].
Bello, Ezia ;
Colella, Gennaro ;
Scarlato, Valentina ;
Oliva, Paolo ;
Berndt, Alexander ;
Valbusa, Giovanni ;
Serra, Sonia Colombo ;
D'Incalci, Maurizio ;
Cavalletti, Ennio ;
Giavazzi, Raffaella ;
Damia, Giovanna ;
Camboni, Gabriella .
CANCER RESEARCH, 2011, 71 (04) :1396-1405
[7]   PDGF, Pericytes and the Pathogenesis of Idiopathic Basal Ganglia Calcification (IBGC) [J].
Betsholtz, Christer ;
Keller, Annika .
BRAIN PATHOLOGY, 2014, 24 (04) :387-395
[8]   Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice [J].
Blaskovich, MA ;
Lin, Q ;
Delarue, FL ;
Sun, J ;
Park, HS ;
Coppola, D ;
Hamilton, AD ;
Sebti, SM .
NATURE BIOTECHNOLOGY, 2000, 18 (10) :1065-1070
[9]   Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma [J].
Boonjaraspinyo, Sirintip ;
Wu, Zhiliang ;
Boonmars, Thidarut ;
Kaewkes, Sasithorn ;
Loilome, Watchalin ;
Sithithaworn, Paiboon ;
Nagano, Isao ;
Takahashi, Yuzo ;
Yongvanit, Puangrat ;
Bhudhisawasdi, Vajarabhongsa .
PARASITOLOGY INTERNATIONAL, 2012, 61 (01) :145-150
[10]   An oncogenic activity of PDGF-C and its splice variant in human breast cancer [J].
Bottrell, Alyssa ;
Meng, Yong Hong ;
Najy, Abdo J. ;
Hurst, Newton ;
Kim, Seongho ;
Kim, Chong Jai ;
Kim, Eun-Sook ;
Moon, Aree ;
Kim, Eun Joo ;
Park, So Yeon ;
Kim, Hyeong-Reh Choi .
GROWTH FACTORS, 2019, 37 (3-4) :131-145
12345678910